Switzerland· 67156003
Esperoct
A coagulation factor viii product containing turoctocogum alfa pegolum, registered in Switzerland and dispensed under Swissmedic category B, on the national reimbursement list. The same ATC class is registered in 11 of our 19 countries.
Checked against BAG Spezialitätenliste (Switzerland) on
Informational only — not a medical device.
Where it is registered
Coagulation factor viii is registered in 11 of 19 countries.
Countries holding a registration under ATC B02BD02 (coagulation factor viii), each read from that country’s own register.
- This record: Switzerland, from BAG Spezialitätenliste (Switzerland)
- 7 of them publish a price we can compare per daily dose
Coagulation factor viii · ATC B02BD02
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
BAG Spezialitätenliste (Switzerland)- Active substance
- turoctocogum alfa pegolum
- Manufacturer
- —
- Country
- Switzerland (CH)
- ATC code
- B02BD02
- ATC class
- Coagulation factor VIII
- Defined daily dose
- 1 TSD, E
- Swissmedic category
- B
- Reimbursed
- Yes
- Source register
- BAG Spezialitätenliste (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin7680671560039Durchstf 1 StkCHF 1189.7
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
4 interactions on record for coagulation factor viii.
Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Coagulation factor viii · interactions on record
4 records
- 2 severe
- 2 moderate
Most severe, free to view
- CarfilzomibL01XG02severe
- CarfilzomibL01XX45severe
- PegvaliaseA16AB19moderate
- EmicizumabB02BX06moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Coagulation factor viii in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandEsperoctOrifarm Oy
- CzechiaESPEROCTNovo Nordisk A/S, Bagsvaerd
- SwedenEsperoct 1000 IE Pulver och vätska till injektionsvätska, lösningNovo Nordisk A/S
- IrelandEsperoct 1000 IU Powder and solvent for solution for injectionNovo Nordisk A/S
- IcelandEsperoctNovo Nordisk A/S*
- NetherlandsEsperoct 1000 IE, poeder en oplosmiddel voor oplossing voor injectieNovo Nordisk A.S.
- PolandEsperoctNovo Nordisk A/S
- BelgiumEsperoct 1000 IUNovo Nordisk
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Esperoct
- Norway · Esperoct
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of BAG Spezialitätenliste (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/bce08570-9c82-4c97-b917-4bca371da95a GET /v1/drugs/bce08570-9c82-4c97-b917-4bca371da95a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "turoctocogum alfa pegolum 1500 UI",
"valid_from": "2024-07-01",
"limitations": null,
"galenic_form": "Trockensub 1500 IE c Solv",
"therapeutic_area": null,
"sl_inclusion_date": "2019-10-01",
"self_retention_pct": 10
}See everything about coagulation factor viii.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.